➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Boehringer Ingelheim
Moodys
McKinsey
Medtronic

Last Updated: August 4, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,540,382


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,540,382 protect, and when does it expire?

Patent 9,540,382 protects IMBRUVICA and is included in one NDA.

This patent has fifty-nine patent family members in twenty-eight countries.

Summary for Patent: 9,540,382
Title:Crystalline forms of a Bruton's tyrosine kinase inhibitor
Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pi- peridin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Purro; Norbert (Los Gatos, CA), Smyth; Mark (Foster City, CA), Goldman; Erick (Concord, CA), Wirth; David D. (Oak Ridge, NC)
Assignee: Pharmacyclics LLC (Sunnyvale, CA)
Application Number:14/405,317
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,540,382
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Device; Dosage form;

Drugs Protected by US Patent 9,540,382

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA ⤷  Free Forever Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA ⤷  Free Forever Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA ⤷  Free Forever Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF MANTLE CELL LYMPHOMA ⤷  Free Forever Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 AB RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF MARGINAL ZONE LYMPHOMA ⤷  Free Forever Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-001 Nov 13, 2013 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial TREATMENT OF MARGINAL ZONE LYMPHOMA ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,540,382

PCT Information
PCT FiledJune 03, 2013PCT Application Number:PCT/US2013/043888
PCT Publication Date:December 12, 2013PCT Publication Number: WO2013/184572

International Family Members for US Patent 9,540,382

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 092844 ⤷  Free Forever Trial
Australia 2013271918 ⤷  Free Forever Trial
Australia 2016250445 ⤷  Free Forever Trial
Australia 2018211201 ⤷  Free Forever Trial
Australia 2018211216 ⤷  Free Forever Trial
Australia 2020239751 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Johnson and Johnson
Express Scripts
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.